Lipid-Based Drug Carriers for Prodrugs to Enhance Drug Delivery

AAPS Journal

Volumn 17, Issue 1, 2015, Pages 83-92

  Zaro, Jennica L ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

drug delivery; fatty acids; glyceride; phospholipid; prodrug

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DRUG CARRIER; LIPID; LIPOPROTEIN; LIPOSOME; NUCLEOSIDE DERIVATIVE; NUCLEOSIDE TRIPHOSPHATE; PRODRUG; DRUG;

ARTICLE; B LYMPHOCYTE; CANCER LOCALIZATION; CELL PROTECTION; CENTRAL NERVOUS SYSTEM; CHEMICAL MODIFICATION; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; LIPID METABOLISM; LIPID STORAGE; LIVER; LYMPH VESSEL; PH; PROTEIN LIPID INTERACTION; T LYMPHOCYTE; CHEMISTRY; DRUG DESIGN; HALF LIFE TIME; METABOLISM; TISSUE DISTRIBUTION;

DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HALF-LIFE; HUMANS; LIPIDS; PHARMACEUTICAL PREPARATIONS; PRODRUGS; TISSUE DISTRIBUTION;

EID: 84920553510     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-014-9670-z     Document Type: Article

References (96)

1. Smith DA, Brown K, Neale MG. Chromone-2-carboxylic acids: roles of acidity and lipophilicity in drug disposition. Drug Metab Rev. 1985;16(4):365–88.
2. van der Vusse GJ. Albumin as fatty acid transporter. Drug Metab Pharmacokinet. 2009;24(4):300–7.
3. Hackett MJ, Zaro JL, Shen WC, Guley PC, Cho MJ. Fatty acids as therapeutic auxiliaries for oral and parenteral formulations. Adv Drug Deliv Rev. 2013;65(10):1331–9.
4. Wermuth CG GJ-C, Marchandeau C. Designing prodrugs and bioprecursors I: carrier prodrugs. In: CG W, editor. The practice of medicinal chemistry. London: Academic; 1996. p. 671–96.
5. Clayton JP, Cole M, Elson SW, Ferres H. BRL.8988 (talampicillin), a well-absorbed oral form of ampicillin. Antimicrob Agents Chemother. 1974;5(6):670–1.
6. Minto CF, Howe C, Wishart S, Conway AJ, Handelsman DJ. Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: effects of ester, injection site and injection volume. J Pharmacol Exp Ther. 1997;281(1):93–102.
7. Christie WW, editor. Advances in lipid methodology. Dundee: Oily Press; 1993.
8. Taylor MD. Improved passive oral delivery via prodrugs. Adv Drug Deliv Rev. 1996;19(2):131–48.
9. Yanez JA, Wang SW, Knemeyer IW, Wirth MA, Alton KB. Intestinal lymphatic transport for drug delivery. Adv Drug Deliv Rev. 2011;63(10–11):923–42.
10. Charbon V, Latour I, Lambert DM, Buc-Calderon P, Neuvens L, De Keyser JL, et al. Targeting of drug to the hepatocytes by fatty acids. Influence of the carrier (albumin or galactosylated albumin) on the fate of the fatty acids and their analogs. Pharm Res. 1996;13(1):27–31.
11. Sasson K, Marcus Y, Lev-Goldman V, Rubinraut S, Fridkin M, Shechter Y. Engineering prolonged-acting prodrugs employing an albumin-binding probe that undergoes slow hydrolysis at physiological conditions. J Control Release: Off J Control Release Society. 2010;142(2):214–20.
12. Caliph SM, Charman WN, Porter CJ. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. J Pharm Sci. 2000;89(8):1073–84.
13. Paris GY, Garmaise DL, Cimon DG, Swett L, Carter GW, Young P. Glycerides as prodrugs. 2. 1,3-Dialkanoyl-2-(2-methyl-4-oxo-1,3-benzodioxan-2-yl)glycerides (cyclic aspirin triglycerides) as antiinflammatory agents. J Med Chem. 1980;23(1):79–82.
14. Paris GY, Garmaise DL, Cimon DG, Swett L, Carter GW, Young P. Glycerides as prodrugs. 3. Synthesis and antiinflammatory activity of [1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetyl]glycerides (indomethacin glycerides). J Med Chem. 1980;23(1):9–13.
15. Cullen E. Novel anti-inflammatory agents. J Pharm Sci. 1984;73(5):579–89.
16. Delie F, Couvreur P, Nisato D, Michel JB, Puisieux F, Letourneux Y. Synthesis and in vitro study of a diglyceride prodrug of a peptide. Pharm Res. 1994;11(8):1082–7.
17. Scriba GK, Lambert DM. Bioavailability of phenytoin and anticonvulsant activity after oral administration of phenytoin-bis-hydroxyisobutyrate to rats. Pharm Res. 1997;14(2):251–3.
18. Garzonaburbeh A, Poupaert JH, Claesen M, Dumont P, Atassi G. 1,3-Dipalmitoylglycerol ester of chlorambucil as a lymphotropic, orally administrable anti-neoplastic agent. J Med Chem. 1983;26(8):1200–3.
19. Garzonaburbeh A, Poupaert JH, Claesen M, Dumont P. A lymphotropic prodrug of L-dopa—synthesis, pharmacological properties, and pharmacokinetic behavior of 1,3-dihexadecanoyl-2-[(S)-2-amino-3-(3,4-dihydroxyphenyl)propanoyl]propane-1,2,3-triol. J Med Chem. 1986;29(5):687–91.
20. Lambert DM. Rationale and applications of lipids as prodrug carriers. Eur J Pharm Sci: Off J Eur Fed Pharm Sci. 2000;11 Suppl 2:S15–27.
21. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615–27.
22. Prodrugs: challenges and rewards. New York: Springer; 2007.
23. Ojima I, Slater JC, Michaud E, Kuduk SD, Bounaud PY, Vrignaud P, et al. Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells. J Med Chem. 1996;39(20):3889–96.
24. Raub TJ. P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol Pharm. 2006;3(1):3–25.
25. Ruchelman AL, Houghton PJ, Zhou N, Liu A, Liu LF, LaVoie EJ. 5-(2-aminoethyl)dibenzo[c, h][1,6]naphthyridin-6-ones: variation of n-alkyl substituents modulates sensitivity to efflux transporters associated with multidrug resistance. J Med Chem. 2005;48(3):792–804.
26. Wechter WJ, Johnson MA, Hall CM, Warner DT, Berger AE, Wenzel AH, et al. ara-Cytidine acrylates. Use of drug design predictors in structure-activity relationship correlation. J Med Chem. 1975;18(4):339–44.
27. Neil GL, Wiley PF, Manak RC, Moxley TE. Antitumor effect of 1-beta-D-arabinofuranosylcytosine 5′-adamantoate (NSC 117614) in L1210 leukemic mice. Cancer Res. 1970;30(4):1047–54.
28. Wechter WJ, Gish DT, Greig ME, Gray GD, Moxley TE, Kuentzel SL, et al. Nucleic acids. 16. Orally active derivatives of ara-cytidine. J Med Chem. 1976;19(8):1013–7.
29. Bergman AM, Kuiper CM, Noordhuis P, Smid K, Voorn DA, Comijn EM, et al. Antiproliferative activity and mechanism of action of fatty acid derivatives of gemcitabine in leukemia and solid tumor cell lines and in human xenografts. Nucleosides Nucleotides Nucleic Acids. 2004;23(8–9):1329–33.
30. Peters GJ, Voorn DA, Kuiper CM, van der Wilt CL, Noordhuis P, Smid K, et al. Cell specific cytotoxicity and structure-activity relationship of lipophilic 1-B-D-arabinofuranosylcytosine (ara-C) derivatives. Nucleosides Nucleotides. 1999;18(4–5):877–8. Epub 1999/08/05.
31. Breistol K, Balzarini J, Sandvold ML, Myhren F, Martinsen M, De Clercq E, et al. Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models. Cancer Res. 1999;59(12):2944–9.
32. Jordheim LP, Cros E, Gouy MH, Galmarini CM, Peyrottes S, Mackey J, et al. Characterization of a gemcitabine-resistant murine leukemic cell line: reversion of in vitro resistance by a mononucleotide prodrug. Clin Cancer Res: Off J Am Assoc Cancer Res. 2004;10(16):5614–21.
33. Tobias SC, Borch RF. Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug. Mol Pharm. 2004;1(2):112–6.
34. Raetz CR, Chu MY, Srivastava S, Turcotte JG. A phospholipid derivative of cytosine arabinoside and its conversion to phosphatidylinositol by animal tissue. Science. 1977;196(4287):303–5.
35. Ludwig PS, Schwendener RA, Schott H. Synthesis and anticancer activities of amphiphilic 5-fluoro-2′-deoxyuridylic acid prodrugs. Eur J Med Chem. 2005;40(5):494–504.
36. Peghini PA, Zahner R, Kuster H, Schott H, Schwendener RA. In vitro anti-human immunodeficiency virus and anti-hepatitis B virus activities and pharmacokinetic properties of heterodinucleoside phosphates containing AZT or ddC. Antivir Chem Chemother. 1998;9(2):117–26.
37. Galmarini CM, Myhren F, Sandvold ML. CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines. Br J Haematol. 2009;144(2):273–5.
38. Immordino ML, Brusa P, Rocco F, Arpicco S, Ceruti M, Cattel L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. J Control Release: off J Controll Release Soc. 2004;100(3):331–46.
39. Ali SM, Khan AR, Ahmad MU, Chen P, Sheikh S, Ahmad I. Synthesis and biological evaluation of gemcitabine-lipid conjugate (NEO6002). Bioorg Med Chem Lett. 2005;15(10):2571–4.
40. Chen P, Chien PY, Khan AR, Sheikh S, Ali SM, Ahmad MU, et al. In-vitro and in-vivo anti-cancer activity of a novel gemcitabine-cardiolipin conjugate. Anti-Cancer Drugs. 2006;17(1):53–61.
41. Adema AD, Radi M, Daft J, Narayanasamy J, Hoebe EK, Alexander LE, et al. Troxacitabine prodrugs for pancreatic cancer. Nucleosides Nucleotides Nucleic Acids. 2007;26(8–9):1073–7.
42. Senter PD, Pearce WE, Greenfield RS. Development of a drug-release strategy based on the reductive fragmentation of benzyl carbamate disulfides. J Org Chem. 1990;55(9):2975–8.
43. Wang Y, Li L, Jiang W, Yang Z, Zhang Z. Synthesis and preliminary antitumor activity evaluation of a DHA and doxorubicin conjugate. Bioorg Med Chem Lett. 2006;16(11):2974–7.
44. Kuznetsova L, Chen J, Sun L, Wu XY, Pepe A, Veith JA, et al. Syntheses and evaluation of novel fatty acid-second-generation taxoid conjugates as promising anticancer agents. Bioorg Med Chem Lett. 2006;16(4):974–7.
45. Hostetler KY, Beadle JR, Hornbuckle WE, Bellezza CA, Tochkov IA, Cote PJ, et al. Antiviral activities of oral 1-O-hexadecylpropanediol-3-phosphoacyclovir and acyclovir in woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother. 2000;44(7):1964–9.
46. Suto T, Miyazawa J, Watanabe Y, Suto K, Yoshida Y, Sakata Y. The effect of YNK-01 (an oral prodrug of cytarabine) on hepatocellular carcinoma. Semin Oncol. 1997;24(6):S6-122–S6-9.
47. Tauber U, Schroder K, Dusterberg B, Matthes H. Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone. Eur J Drug Metab Pharmacokinet. 1986;11(2):145–9.
48. Horst HJ, Holtje WJ, Dennis M, Coert A, Geelen J, Voigt KD. Lymphatic absorption and metabolism of orally administered testosterone undecanoate in man. Klin Wochenschr. 1976;54(18):875–9.
49. Coert A, Geelen J, de Visser J, van der Vies J. The pharmacology and metabolism of testosterone undecanoate (TU), a new orally active androgen. Acta Endocrinol (Copenh). 1975;79(4):789–800.
50. Cense HA, van Eijck CH, Tilanus HW. New insights in the lymphatic spread of oesophageal cancer and its implications for the extent of surgical resection. Best Pract Res Clin Gastroenterol. 2006;20(5):893–906.
51. Garzon-Aburbeh A, Poupaert JH, Claesen M, Dumont P, Atassi G. 1,3-dipalmitoylglycerol ester of chlorambucil as a lymphotropic, orally administrable antineoplastic agent. J Med Chem. 1983;26(8):1200–3.
52. Pantaleo G, Graziosi C, Fauci AS. The role of lymphoid organs in the immunopathogenesis of HIV infection. AIDS. 1993;7 Suppl 1:S19–23.
53. Pantaleo G, Graziosi C, Demarest JF, Cohen OJ, Vaccarezza M, Gantt K, et al. Role of lymphoid organs in the pathogenesis of human immunodeficiency virus (HIV) infection. Immunol Rev. 1994;140:105–30.
54. Umeda M, Marusawa H, Seno H, Katsurada A, Nabeshima M, Egawa H, et al. Hepatitis B virus infection in lymphatic tissues in inactive hepatitis B carriers. J Hepatol. 2005;42(6):806–12.
55. Shackleford DM, Faassen WA, Houwing N, Lass H, Edwards GA, Porter CJH, et al. Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol formulations in conscious lymph duct-cannulated dogs. J Pharmacol Exp Ther. 2003;306(3):925–33.
56. Allen TM, Hansen C. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta. 1991;1068(2):133–41.
57. Newman MS, Colbern GT, Working PK, Engbers C, Amantea MA. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol. 1999;43(1):1–7.
58. Liposome technology. Boca Raton: CRC Press; 1992
59. Korba BA, Xie H, Wright KN, Hornbuckle WE, Gerin JL, Tennant BC, et al. Liver-targeted antiviral nucleosides: enhanced antiviral activity of phosphatidyl-dideoxyguanosine versus dideoxyguanosine in woodchuck hepatitis virus infection in vivo. Hepatology. 1996;23(5):958–63.
60. Taneja D, Namdeo A, Mishra PR, Khopade AJ, Jain NK. High-entrapment liposomes for 6-mercaptopurine—a prodrug approach. Drug Dev Ind Pharm. 2000;26(12):1315–9.
61. Tokunaga Y, Iwasa T, Fujisaki J, Sawai S, Kagayama A. Liposomal sustained-release delivery systems for intravenous injection V. Biological disposition of liposome-entrapped lipophilic prodrug of 1-beta-D-arabinofuranosylcytosine. Chem Pharm Bull. 1988;36(10):4060–7.
62. Tokunaga Y, Iwasa T, Fujisaki J, Sawai S, Kagayama A. Liposomal sustained-release delivery systems for intravenous injection. IV. Antitumor activity of newly synthesized lipophilic 1-beta-D-arabinofuranosylcytosine prodrug-bearing liposomes. Chem Pharm Bull. 1988;36(9):3574–83.
63. Bundgaard H, Falch E, Larsen C, Mikkelson TJ. Pilocarpine prodrugs. 1. Synthesis, physicochemical properties and kinetics of lactonization of pilocarpic acid-esters. J Pharm Sci. 1986;75(1):36–43.
64. Burke TG, Mishra AK, Wani MC, Wall ME. Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry. 1993;32(20):5352–64.
65. Bundgaard H. The double prodrug concept and its applications. Adv Drug Deliv Rev. 1989;3(1):39–65.
66. Arouri A, Hansen AH, Rasmussen TE, Mouritsen OG. Lipases, liposomes and lipid-prodrugs. Curr Opin Colloid In. 2013;18(5):419–31.
67. Park YS. Tumor-directed targeting of liposomes. Biosci Rep. 2002;22(2):267–81.
68. Noble GT, Stefanick JF, Ashley JD, Kiziltepe T, Bilgicer B. Ligand-targeted liposome design: challenges and fundamental considerations. Trends Biotechnol. 2014;32(1):32–45.
69. Shum P, Kim JM, Thompson DH. Phototriggering of liposomal drug delivery systems. Adv Drug Deliv Rev. 2001;53(3):273–84.
70. Lee H, Messersmith P. Bio-inspired nanomaterials for a new generation of medicine. In: Vo-Dihn T, editor. Nanotechnology in biology and medicine: methods, devices, and applications. Boca Raton, Florida: CRC Press; 2007. p. 3–1–3–20.
71. Ganta S, Devalapally H, Shahiwala A, Amiji M. A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control Release. 2008;126(3):187–204. Epub 2008/02/12.
72. Sabnis N, Lacko AG. Drug delivery via lipoprotein-based carriers: answering the challenges in systemic therapeutics. Ther Deliv. 2012;3(5):599–608.
73. Firestone RA. Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconjug Chem. 1994;5(2):105–13.
74. Yen CF, Kalunta CI, Chen FS, Kaptein JS, Lin CK, Lad PM. Flow cytometric evaluation of LDL receptors using DiI-LDL uptake and its application to B and T lymphocytic cell lines. J Immunol Methods. 1994;177(1–2):55–67.
75. Nikanjam M, Gibbs AR, Hunt CA, Budinger TF, Forte TM. Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J Control Release: offi J Controll Release Soc. 2007;124(3):163–71.
76. Koller-Lucae SK, Schott H, Schwendener RA. Low density lipoprotein and liposome mediated uptake and cytotoxic effect of N4-octadecyl-1-beta-D-arabinofuranosylcytosine in Daudi lymphoma cells. Br J Cancer. 1999;80(10):1542–9.
77. Versluis AJ, Rensen PC, Rump ET, Van Berkel TJ, Bijsterbosch MK. Low-density lipoprotein receptor-mediated delivery of a lipophilic daunorubicin derivative to B16 tumours in mice using apolipoprotein E-enriched liposomes. Br J Cancer. 1998;78(12):1607–14.
78. Bibby DC, Charman WN, Charman SA, Iskander MN, Porter CJH. Synthesis and evaluation of 5′ alkyl ester prodrugs of zidovudine for directed lymphatic delivery. Int J Pharm. 1996;144(1):61–70.
79. Fernandez E, Borgstrom B. Intestinal-absorption of retinol and retinyl palmitate in the Rat—effects of tetrahydrolipstatin. Lipids. 1990;25(9):549–52.
80. Noguchi T, Charman WNA, Stella VJ. The effect of drug lipophilicity and lipid vehicles on the lymphatic absorption of various testosterone esters. Int J Pharm. 1985;24(2–3):173–84.
81. Deverre JR, Loiseau P, Puisieux F, Gayral P, Letourneux Y, Couvreur P, et al. Synthesis of the orally macrofilaricidal and stable glycerolipidic prodrug of melphalan, 1,3-dipalmitoyl-2-(4′(bis(2″-chloroethyl)amino)phenylalaninoyl)glycerol. Arzneimittelforschung. 1992;42–2(9):1153–6.
82. Loiseau PM, Deverre JR, Elkihel L, Gayral P, Letourneux Y. Study of lymphotropic targeting and macrofilaricidal activity of a melphalan prodrug on the Molinema-dessetae model. J Chemother. 1994;6(4):230–7.
83. Carter GW, Young PR, Swett LR, Paris GY. Pharmacological studies in the rat with [2-(1,3-didecanoyloxy)-propyl]2-acetyloxybenzoate (a-45474)—an aspirin pro-drug with negligible gastric irritation. Agents Actions. 1980;10(3):240–5.
84. Sakai A, Mori N, Shuto S, Suzuki T. Deacylation reacylation cycle—a possible absorption mechanism for the novel lymphotropic antitumor agent dipalmitoylphosphatidylfluorouridine in rats. J Pharm Sci. 1993;82(6):575–8.
85. Hara T, Liu F, Liu DX, Huang L. Emulsion formulations as a vector for gene delivery in vitro and in vivo. Adv Drug Deliv Rev. 1997;24(2–3):265–71.
86. Hara T, Tan Y, Huang L. In vivo gene delivery to the liver using reconstituted chylomicron remnants as a novel nonviral vector. Proc Natl Acad Sci U S A. 1997;94(26):14547–52.
87. Rensen PC, de Vrueh RL, van Berkel TJ. Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations. Clin Pharmacokinet. 1996;31(2):131–55.
88. Shawer M, Greenspan P, OI S, Lu DR. VLDL-resembling phospholipid-submicron emulsion for cholesterol-based drug targeting. J Pharm Sci. 2002;91(6):1405–13.
89. Kader A, Pater A. Loading anticancer drugs into HDL as well as LDL has little affect on properties of complexes and enhances cytotoxicity to human carcinoma cells. J Control Release: off J Controll Release Soc. 2002;80(1–3):29–44.
90. Chu AC, Tsang SY, Lo EH, Fung KP. Low density lipoprotein as a targeted carrier for doxorubicin in nude mice bearing human hepatoma HepG2 cells. Life Sci. 2001;70(5):591–601.
91. Tauchi Y, Takase M, Zushida I, Chono S, Sato J, Ito K, et al. Preparation of a complex of dexamethasone palmitate-low density lipoprotein and its effect on foam cell formation of murine peritoneal macrophages. J Pharm Sci. 1999;88(7):709–14.
92. Li H, Zhang Z, Blessington D, Nelson DS, Zhou R, Lund-Katz S, et al. Carbocyanine labeled LDL for optical imaging of tumors. Acad Radiol. 2004;11(6):669–77.
93. Kim JS, Kim BI, Maruyama A, Akaike T, Kim SW. A new non-viral DNA delivery vector: the terplex system. J Control Release. 1998;53(1–3):175–82.
94. Kim JS, Maruyama A, Akaike T, Kim SW. In vitro gene expression on smooth muscle cells using a terplex delivery system. J Control Release. 1997;47(1):51–9.
95. Lacko AG, Nair M, Paranjape S, Johnso S, McConathy WJ. High density lipoprotein complexes as delivery vehicles for anticancer drugs. Anticancer Res. 2002;22(4):2045–9.
96. Bijsterbosch MK, Schouten D, van Berkel TJ. Synthesis of the dioleoyl derivative of iododeoxyuridine and its incorporation into reconstituted high density lipoprotein particles. Biochemistry. 1994;33(47):14073–80.